Biotech
-
Australian Treasurer Jim Chalmers Faces Backlash Over R&D Tax Policy and Administrative Failures
Australian Treasurer Jim Chalmers is under fire from the biotech sector over R&D tax changes and a high-profile administrative error involving a midwife’s refund.
-
uniQure to Submit Huntington’s Gene Therapy for FDA Approval
Gene therapy developer uniQure announced plans to submit a Biologics License Application for its Huntington’s disease treatment, AMT-130, following positive feedback from the FDA.
-
The Peptide Paradox: Balancing Rapid Market Growth with Regulatory Compliance
As peptides expand from wellness trends to agricultural and pharmaceutical staples, regulators are tightening oversight on compounding standards and manufacturing precision.
-
Verve-102 Gene Therapy Demonstrates Significant LDL-C Reduction in Phase 1b Trial
New clinical data from the Heart-2 trial reveals that a single dose of the gene therapy VERVE-102 can reduce ‘bad’ cholesterol by up to 62%, marking a potential shift from chronic cardiovascular management to one-time intervention.
-
Deep Learning Hits Human-Level Precision in Biology and Medicine
New deep learning frameworks are transforming complex biological analysis, from mapping inflammatory memory to enhancing cardiac diagnostics, matching human-level accuracy.
-
New Pathway Found to Combat Diabetic Ulcer Inflammation
Researchers have identified a molecular axis involving the STING pathway that drives diabetic ulcer development, offering a potential new therapeutic target.
-
Quantum-Si Raises $50 Million to Strengthen Proteomics Leadership
Quantum-Si Incorporated (Nasdaq: QSI), a trailblazer in next-generation protein sequencing, has announced a $50 million registered direct offering, a critical move to enhance its financial stability and drive growth in the competitive proteomics industry. The offering, priced at $3.20 per…